GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Unity Biotechnology Inc (NAS:UBX) » Definitions » EBIT per Share

Unity Biotechnology (Unity Biotechnology) EBIT per Share : $-2.23 (TTM As of Mar. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Unity Biotechnology EBIT per Share?

Unity Biotechnology's EBIT per Share for the three months ended in Mar. 2024 was $-0.35. Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2024 was $-2.23.

During the past 3 years, the average EBIT per Share Growth Rate was 47.20% per year. During the past 5 years, the average EBIT per Share Growth Rate was 36.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Unity Biotechnology's EBIT per Share or its related term are showing as below:

UBX' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: 27.4   Med: 33.8   Max: 48.6
Current: 47.2

During the past 8 years, the highest 3-Year average EBIT per Share Growth Rate of Unity Biotechnology was 48.60% per year. The lowest was 27.40% per year. And the median was 33.80% per year.

UBX's 3-Year EBIT Growth Rate is ranked better than
92.56% of 1303 companies
in the Biotechnology industry
Industry Median: 3.6 vs UBX: 47.20

Unity Biotechnology's EBIT for the three months ended in Mar. 2024 was $-5.79 Mil.


Unity Biotechnology EBIT per Share Historical Data

The historical data trend for Unity Biotechnology's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Unity Biotechnology EBIT per Share Chart

Unity Biotechnology Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EBIT per Share
Get a 7-Day Free Trial -18.84 -18.20 -10.31 -4.31 -2.53

Unity Biotechnology Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EBIT per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.30 -0.78 -1.02 -0.10 -0.35

Unity Biotechnology EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Unity Biotechnology's EBIT per Share for the fiscal year that ended in Dec. 2023 is calculated as

EBIT per Share(A: Dec. 2023 )
=EBIT/Shares Outstanding (Diluted Average)
=-37.408/14.774
=-2.53

Unity Biotechnology's EBIT per Share for the quarter that ended in Mar. 2024 is calculated as

EBIT per Share(Q: Mar. 2024 )
=EBIT/Shares Outstanding (Diluted Average)
=-5.79/16.785
=-0.34

EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.23

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Unity Biotechnology  (NAS:UBX) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.


Unity Biotechnology EBIT per Share Related Terms

Thank you for viewing the detailed overview of Unity Biotechnology's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Unity Biotechnology (Unity Biotechnology) Business Description

Traded in Other Exchanges
Address
285 East Grand Avenue, South San Francisco, CA, USA, 94080
Unity Biotechnology Inc designs therapeutics that prevent, halt, and reverse various diseases of aging. The company focuses on clearing senescent cells, and creating senolytic medicines. Its medicines target vulnerabilities unique to senescent cells to clear those cells from the human body while leaving normal cells unaffected. The firm focuses on age-associated diseases such as osteoarthritis, eye diseases, and pulmonary diseases.
Executives
Anirvan Ghosh director, officer: Chief Executive Officer C/O UNITY BIOTECHNOLOGY, INC., 285 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Jamie Dananberg officer: Chief Medical Officer 3280 BAYSHORE BOULEVARD, BRISBANE CA 94005
Michael P. Samar director C/O ASSEMBLY BIOSCIENCES, INC., 11711 N. MERIDIAN ST. SUITE 310, CARMEL IN 46032
Alexander Hieu Nguyen officer: See Remarks C/O UNITY BIOTECHNOLOGY, INC., 285 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Nathaniel E David director, officer: President C/O KYTHERA BIOPHARMACEUTICALS, INC., 27200 WEST AGOURA ROAD, SUITE 200, CALABASAS CA 91301
Gilmore Neil O'neill director 215 FIRST STREET, CAMBRIDGE MA 02142
Alexander Azoy officer: See Remarks 30699 RUSSELL RANCH ROAD, SUITE 140, WESTLAKE VILLAGE CA 91362
Lynne Marie Sullivan officer: See Remarks C/O SOLID BIOSCIENCES, LLC, 141 PORTLAND STREET, FIFTH FLOOR, CAMBRIDGE MA 02139
Robert Nelsen director 8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Graham K Cooper director C/O RECEPTOS, INC., 10835 ROAD TO THE CURE, SUITE 205, SAN DIEGO CA 92121
Paul L Berns director 11080 CIRCLEPOINT RD., STE, 200, WESTMINSTER CO 80020
Camille D Samuels director 2463 JACKSON ST., SAN FRANCISCO CA 94115
Kristina Burow director 8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
David L. Lacey director 3280 BAYSHORE BOULEVARD, BRISBANE CA 94005
Dan Marquess officer: Chief Scientific Officer 3280 BAYSHORE BOULEVARD, BRISBANE CA 94005

Unity Biotechnology (Unity Biotechnology) Headlines